These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9952390)

  • 1. Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin.
    Cooper PJ; Awadzi K; Ottesen EA; Remick D; Nutman TB
    J Infect Dis; 1999 Mar; 179(3):738-42. PubMed ID: 9952390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin.
    Cooper PJ; Schwartz LB; Irani AM; Awadzi K; Guderian RH; Nutman TB
    J Infect Dis; 2002 Nov; 186(9):1307-13. PubMed ID: 12402200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokines in onchocerciasis patients after a single dose of ivermectin.
    Fendt J; Hamm DM; Banla M; Schulz-Key H; Wolf H; Helling-Giese G; Heuschkel C; Soboslay PT
    Clin Exp Immunol; 2005 Nov; 142(2):318-26. PubMed ID: 16232219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly.
    Kamgno J; Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Duke BO; Boussinesq M
    Trans R Soc Trop Med Hyg; 2004 Aug; 98(8):496-504. PubMed ID: 15186939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions to ivermectin treatment in Simulium neavei-transmitted onchocerciasis.
    Kipp W; Bamhuhiiga J; Rubaale T; Büttner DW
    Am J Trop Med Hyg; 2003 Dec; 69(6):621-3. PubMed ID: 14740878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin.
    Awadzi K; Opoku NO; Addy ET; Quartey BT
    Trop Med Parasitol; 1995 Jun; 46(2):131-7. PubMed ID: 8525285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results.
    Fobi G; Gardon J; Kamgno J; Aimard-Favennec L; Lafleur C; Gardon-Wendel N; Duke BO; Boussinesq M
    Trans R Soc Trop Med Hyg; 2005 Apr; 99(4):279-89. PubMed ID: 15708387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RANTES in onchocerciasis: changes with ivermectin treatment.
    Cooper PJ; Guderian RH; Prakash D; Remick DG; Espinel I; Nutman TB; Taylor DW; Griffin GE
    Clin Exp Immunol; 1996 Dec; 106(3):462-7. PubMed ID: 8973613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus.
    Awadzi K; Edwards G; Duke BO; Opoku NO; Attah SK; Addy ET; Ardrey AE; Quartey BT
    Ann Trop Med Parasitol; 2003 Mar; 97(2):165-78. PubMed ID: 12803872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection.
    Turner JD; Mand S; Debrah AY; Muehlfeld J; Pfarr K; McGarry HF; Adjei O; Taylor MJ; Hoerauf A
    Clin Infect Dis; 2006 Apr; 42(8):1081-9. PubMed ID: 16575724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.
    Yamazaki K; Suzuki K; Nakamura A; Sato S; Lindor KD; Batts KP; Tarara JE; Kephart GM; Kita H; Gleich GJ
    Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivermectin--clinical trials and treatment schedules in onchocerciasis.
    Brown KR; Neu DC
    Acta Leiden; 1990; 59(1-2):169-75. PubMed ID: 2198749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions.
    Keiser PB; Reynolds SM; Awadzi K; Ottesen EA; Taylor MJ; Nutman TB
    J Infect Dis; 2002 Mar; 185(6):805-11. PubMed ID: 11920298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
    Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
    Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community treatment with ivermectin for onchocerciasis in the east Usambara mountains.
    Mwetta E; Hills E
    East Afr Med J; 1994 Dec; 71(12):790-1. PubMed ID: 7705249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia.
    Kanza EM; Nyathirombo A; Larbelee JP; Opoku NO; Bakajika DK; Howard HM; Mambandu GL; Nigo MM; Wonyarossi DU; Ngave F; Kennedy KK; Kataliko K; Bolay KM; Attah SK; Olipoh G; Asare S; Mumbere M; Vaillant M; Halleux CM; Kuesel AC
    Parasit Vectors; 2024 Mar; 17(1):137. PubMed ID: 38491528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis.
    Limaye AP; Abrams JS; Silver JE; Awadzi K; Francis HF; Ottesen EA; Nutman TB
    J Clin Invest; 1991 Oct; 88(4):1418-21. PubMed ID: 1918387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure.
    Henry NL; Law M; Nutman TB; Klion AD
    J Infect Dis; 2001 Feb; 183(3):512-6. PubMed ID: 11133386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?
    Kipp W; Bamhuhiiga J; Rubaale T; Kabagambe G
    Ann Trop Med Parasitol; 2005 Jun; 99(4):395-402. PubMed ID: 15949187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg).
    Kamgno J; Pion SD; Tejiokem MC; Twum-Danso NA; Thylefors B; Boussinesq M
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):777-85. PubMed ID: 17531279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.